Biotech Breakthrough: TLX Surges 20% on Illuccix PSMA-PET Imaging Agent Approval
In a market where biotechnology stocks are often shrouded in uncertainty, Telix Pharmaceuticals (TLX) has emerged as one of the biggest gainers today. With its stock price surging by 20.51% to $23.50 per share, investors are taking notice. Telix is a clinical-stage oncology company that’s developing and commercializing therapeutic and diagnostic radiopharmaceuticals for various types … Read more